Citigroup Inc Arbutus Biopharma Corp Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Citigroup Inc holds 1,141,313 shares of ABUS stock, worth $4.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,141,313

Previous 226,888 403.03%

Holding current value

$4.5 Million

Previous $585,000 502.74%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$2.52 - $3.63 $2.3 Million - $3.32 Million	914,425 Added 403.03%	1,141,313 $3.53 Million
Q1 2024 May 10, 2024	BUY	$2.26 - $2.92 $464,662 - $600,360	205,603 Added 965.95%	226,888 $585,000
Q4 2023 Feb 09, 2024	SELL	$1.69 - $2.54 $198,694 - $298,630	-117,571 Reduced 84.67%	21,285 $53,000
Q3 2023 Nov 09, 2023	BUY	$1.9 - $2.27 $116,086 - $138,692	61,098 Added 78.57%	138,856 $281,000
Q2 2023 Aug 10, 2023	BUY	$2.24 - $3.06 $170,190 - $232,492	75,978 Added 4268.43%	77,758 $178,000
Q1 2023 May 11, 2023	SELL	$2.23 - $3.1 $2,214 - $3,078	-993 Reduced 35.81%	1,780 $5,000
Q4 2022 Feb 09, 2023	SELL	$1.91 - $2.85 $1,249 - $1,863	-654 Reduced 19.08%	2,773 $6,000
Q3 2022 Nov 10, 2022	SELL	$1.88 - $2.88 $11,599 - $17,769	-6,170 Reduced 64.29%	3,427 $7,000
Q2 2022 Aug 10, 2022	BUY	$1.98 - $3.17 $5,549 - $8,885	2,803 Added 41.26%	9,597 $26,000
Q1 2022 May 12, 2022	SELL	$2.42 - $3.98 $43,221 - $71,082	-17,860 Reduced 72.44%	6,794 $20,000
Q4 2021 Feb 10, 2022	BUY	$3.11 - $4.61 $31,022 - $45,984	9,975 Added 67.95%	24,654 $96,000
Q3 2021 Nov 10, 2021	BUY	$2.65 - $4.62 $38,899 - $67,816	14,679 New	14,679 $63,000

Others Institutions Holding ABUS

# of Institutions

138

Shares Held

95.4M

Call Options Held

3.44M

Put Options Held

377K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $591M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account